Doom & Gloom for one of Silicon Valley's Brightest Stars

Despite Elizabeth Holmes’s best attempt at looking like Steve Jobs, her imitation game falls short in the world of business success. The last half-year has been increasingly trying for her company-- former media darling Theranos-- since the WSJ first broke news that the blood-testing company was having issues with its offerings. Back in February, its key relationship with major drugstore chain Walgreens was under heavy fire; now, the SEC is checking the company out, in addition to a criminal investigation launched by federal prosecutors. From the article:


Federal officials began requesting information about Theranos in January and February, according to the people familiar with the matter. Those informal requests were followed by grand-jury subpoenas from a federal court in San Francisco in March, the people said. Agents from the Federal Bureau of Investigation and U.S. Postal Inspection Service are assisting in the investigation, the people said.

And the cherry on top? Federal regulators are looking to ban both Holmes and Theranos president Sunny Balwani from owning or operating any lab for the next two years. While certainly a unique case, these recent allegations, along with the devaluing of tech investments by large asset managers might just be a sign of the end of Silicon Valley’s current boom cycle. Anybody willing to wager on whether or not this is Holmes's last hurrah?

 

I've been watching Theranos ever since it came out of stealth. I don't think the entire premise of the business is a fraud.. What I think happened here was a promising technology's potential was blown out of proportion when there was no solid evidence to support that it would work. It seems that every aspect of the business was structured in such a way so as to maximize media attention, from the board of directors featuring luminaries such as Kissinger and David Boies (but no one with extensive in biotechnology) to "female Zuckerberg" story.

Looking back, it seems ludicrous that it rocketed to a $9 billion valuation without a proven product. It makes me wonder how good VCs really are at picking winners. Perhaps most are just lucky and crowd followers.

 

Nulla est et aut voluptate. Est eos voluptates expedita sint. Ab aliquid totam voluptas excepturi perferendis. Voluptatibus temporibus praesentium maxime amet. Voluptatem rerum vel repellendus itaque id vel eius.

Career Advancement Opportunities

April 2024 Investment Banking

  • Jefferies & Company 02 99.4%
  • Goldman Sachs 19 98.8%
  • Harris Williams & Co. New 98.3%
  • Lazard Freres 02 97.7%
  • JPMorgan Chase 03 97.1%

Overall Employee Satisfaction

April 2024 Investment Banking

  • Harris Williams & Co. 18 99.4%
  • JPMorgan Chase 10 98.8%
  • Lazard Freres 05 98.3%
  • Morgan Stanley 07 97.7%
  • William Blair 03 97.1%

Professional Growth Opportunities

April 2024 Investment Banking

  • Lazard Freres 01 99.4%
  • Jefferies & Company 02 98.8%
  • Goldman Sachs 17 98.3%
  • Moelis & Company 07 97.7%
  • JPMorgan Chase 05 97.1%

Total Avg Compensation

April 2024 Investment Banking

  • Director/MD (5) $648
  • Vice President (19) $385
  • Associates (86) $261
  • 3rd+ Year Analyst (14) $181
  • Intern/Summer Associate (33) $170
  • 2nd Year Analyst (66) $168
  • 1st Year Analyst (205) $159
  • Intern/Summer Analyst (145) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
Betsy Massar's picture
Betsy Massar
99.0
3
BankonBanking's picture
BankonBanking
99.0
4
Secyh62's picture
Secyh62
99.0
5
dosk17's picture
dosk17
98.9
6
GameTheory's picture
GameTheory
98.9
7
CompBanker's picture
CompBanker
98.9
8
kanon's picture
kanon
98.9
9
bolo up's picture
bolo up
98.8
10
Jamoldo's picture
Jamoldo
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”